Private: Gallery Post #1

08

Nov2017

INESSS Releases Additional Information on the Continuous Evaluation Process

On November 7, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers announcing further details on the continuous evaluation process. INESSS would like to inform manufacturers that as of November 1, 2017, new terms and conditions apply for manufacturers who wish to request ... Read More

03

Nov2017

INESSS Releases List of Drug Products Currently Being Reviewed Under the Continuous Evaluation Process

On November 2, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) announced they have now published the list of drug products currently undergoing review under their new continuous evaluation process on their website. Citizens, health professionals, patients and their caregivers, as well as their associations or ... Read More

01

Nov2017

PMPRB 2016 Annual Report Released

The Patented Medicine Prices Review Board (PMPRB), in accordance with sections 89 and 100 of the Patent Act, released its Annual Report for the year ended December 31, 2016. The Annual Report is an extensive document that reviews all of the PMPRB’s major activities, analyses of the prices of patented ... Read More

18

Oct2017

RAMQ: October 2017 Update for the List of Medications

The Régie de l’assurance maladie du Québec (RAMQ) released its October update of the List of Medications on October 18, 2017, effective immediately. For more information and to see the list update schedule, please visit the RAMQ website.

17

Oct2017

INESSS Releases Additional Information on the Continuous Evaluation of Drug Products – Mandatory Notification

On October 12, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers announcing the details on the process for the mandatory notification required for submissions. As of November 1, 2017, manufacturers are required to inform INESSS at least 2 months in advance ... Read More

12

Oct2017

CADTH Common Drug Review Releases New Update

On October 11, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 129). Based on feedback from stakeholders, CADTH will be implementing the proposed revision to the resubmission eligibility criteria and a new randomized controlled trial will no longer be required ... Read More

11

Oct2017

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of September 30, 2017:  51 negotiations are currently underway with 6 new files added since the last update of August 31, 2017: Fibristal (ulipristal acetate): Used to treat uterine fibroids (2nd cycle pre-surgery) Glatect ... Read More

29

Sep2017

PMPRB Hearing Panel Decision Released: Soliris

The Hearing Panel of the Patented Medicine Prices Review Board has made public its decision in the matter of Alexion Pharmaceuticals Inc. and the medicine Soliris. The Panel orders Alexion to: pay to Her Majesty in right of Canada an amount calculated by the parties in accordance with Schedule ... Read More

29

Sep2017

INESSS Releases Additional Information on the Continuous Evaluation of Drug Products

On September 29, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers announcing the details on the process for the admissibility of submission applications for registration. A manufacturer can submit an application for registration to INESSS only when all required documents are ... Read More

29

Sep2017

CADTH Common Drug Review Releases New Update

On September 28, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 128) describing the following changes. Revised Procedure for Advance Notification of Pending CDR Submissions and Resubmissions CADTH has received numerous inquiries regarding challenges interpreting and complying with the ... Read More